Possibilities for Preventing Diabetes Among Employees of Defence and Law Enforcement Agencies
Copyright (c) 2025 Hevesi Judit Ildikó
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abstract
Objective: The increasing prevalence of type 2 diabetes mellitus (T2DM) can also impact personnel in defense and law enforcement agencies, as it impairs physical and mental performance, jeopardizing medical fitness and operational readiness. The aim of this study is to explore the possibilities of preventing T2DM among armed forces personnel.
Methods: The research is based on a systematic analysis of epidemiological data, international and national scientific literature, and clinical study results. It examines the applicability of primary, secondary, and tertiary prevention strategies for diabetes within the armed forces.
Results: According to scientific literature and clinical studies, lifestyle interventions effectively reduce the risk of T2DM development and slow the progression of carbohydrate metabolism disorders. Risk-based screening using the FINDRISC questionnaire, combined with appropriate laboratory tests and timely lifestyle modifications, along with pharmacological treatment when necessary, can significantly decrease disease incidence and complications. Modern diabetes management tools, such as continuous glucose monitoring (CGM), support the optimization of individualized therapeutic strategies.
Keywords:
References
A Belügyminisztérium egészségügyi szakmai irányelve a diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemiás kezeléséről és gondozásáról felnőttkorban. Egészségügyi Közlöny, 2023. augusztus 2., 73(13), 1137–1247. Online: http://www.kozlonyok.hu/kozlonyok/Kozlonyok/6/PDF/2023/13.pdf
ALBERTI, G. et al. (2004): Type 2 Diabetes in the Young: The Evolving Epidemic: The International Diabetes Federation Consensus Workshop. Diabetes Care, 27(7), 1798–1811. Online: https://doi.org/10.2337/diacare.27.7.1798
American Diabetes Association (ADA) (2019): Standards of Medical Care in Diabetes Abridged for Primary Care Providers. Clinical Diabetes, 37 (1), 11–34. Online: https://doi.org/10.2337/cd18-0105
American Diabetes Association Professional Practice Committee (2025a): 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement 1), S27–S49. Online: https://doi.org/10.2337/dc25-S002
American Diabetes Association Professional Practice Committee (2025b): 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025. Diabetes Care, 48(Supplement1), S50–S58. Online: https://doi.org/10.2337/dc25-S003
DAVIES, Melanie J. et al. (2022): Management of Hyperglycemia in Type 2 Diabetes, 2022. a Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. Online: https://doi.org/10.2337/dci22-0034
Diabetes Prevention Program Research Group (2015): Long-Term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications Over 15-Year Follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet. Diabetes & Endocrinology, 3(11), 866–875. Online: https://doi.org/10.1016/S2213-8587(15)00291-0
ECHOUFFO-TCHEUGUI, Justin B. et al. (2021): Prediabetes and What It Means: The Epidemiological Evidence. Annual Review of Public Health, 42, 59–77. Online: https://doi.org/10.1146/annurev-publhealth-090419-102644
Emerging Risk Factors Collaboration (2023): Life Expectancy Associated With Different Ages at Diagnosis of Type 2 Diabetes in High-Income Countries: 23 Million Person-Years of Observation. The Lancet Diabetes & Endocrinology, 11(10), 731–742. Online: https://doi.org/10.1016/S2213-8587(23)00223-1
GONG, Qiuhong et al. (2019): Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance: 30-Year Results of the Da Qing Diabetes Prevention Outcome Study. The Lancet. Diabetes & Endocrinology, 7(6), 452–461. Online: https://doi.org/10.1016/S2213-8587(19)30093-2
HAIRE-JOSHU, Debra – HILL-BRIGGS, Felicia (2019): The Next Generation of Diabetes Translation: A Path to Health Equity. Annual Rewiev of Public Health, 40, 391–410. Online:: https://doi.org/10.1146/annurev-publhealth-040218-044158
HEVESI, Judit (2024): Egy krónikus betegség hatása a nemzet stabilitására – tények a cukorbetegségről. Honvédorvos, 76(3–4), 36–52. Online:: https://doi.org/10.29068/HO.2024.3-4.36-52
IDF (2021): Diabetes Atlas. 10th edition. Brussels. Online:https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
JERMENDY, György et al. (2010): A 2-es típusú diabetes és előállapotainak szűrése – módszertani megfontolások, hazai lehetőségek. Orvosi Hetilap, 151(17), 689–695. Online: https://doi.org/10.1556/oh.2010.28818
KEMPLER, Péter (2022): A 2-es típusú cukorbetegség incidenciája, prevalenciája, a kórházi kezelés mutatói és a betegség költségei hazánkban. Diabetologia Hungarica, 30(2), 69–76. Online: https://doi.org/10.24121/dh.2022.5.2
KSH: 22.1.1.10. Halálozások a gyakoribb halálokok és nem szerint. Online: https://www.ksh.hu/stadat_files/nep/hu/nep0010.html
LAITEERAPONG, Neda et al. (2019): The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care, 42(3), 416–426. Online:: https://doi.org/10.2337/dc17-1144
LI, Guangwei et al. (2014): Cardiovascular Mortality, All-Cause Mortality, and Diabetes Incidence After Lifestyle Intervention for People With Impaired Glucose Tolerance in the Da Qing Diabetes Prevention Study: A 23-Year Follow-up Study. The Lancet. Diabetes and Endocrinology, 2(6), 474–480. Online: https://doi.org/10.1016/S2213-8587(14)70057-9
LINDSTRÖM, Jaana et al. (2006): Sustained Reduction in the Incidence of Type 2 Diabetes by Lifestyle Intervention: Follow-up of the Finnish Diabetes Prevention Study. The Lancet, 368(9548), 1673–1679. Online: https://doi.org/10.1016/S0140-6736(06)69701-8
MAJETY, Priyanka et al. (2023): Pharmacological Approaches to the Prevention of Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 14, 1118848. Online: https://doi.org/10.3389/fendo.2023.1118848
MERIKANTO, Ilona H. et al. (2013): Associations of Chronotype and Sleep With Cardiovascular Diseases and Type 2 Diabetes. Chronobiology International, 30(4), 470–477. Online: https://doi.org/10.3109/07420528.2012.741171
NOVÁK, Attila et al. (2017): Harc az elhízás ellen: A Honvéd Testalkati Program. Morfológia és metodika. Honvédségi Szemle, 145(3). Online: https://kiadvany.magyarhonvedseg.hu/index.php/honvszemle/article/view/647/619
PERREAULT, Leigh et al. (2019): Regression from Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care, 42(9), 1809–1815. Online: https://doi.org/10.2337/dc19-0244
WHO (2006): Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Report of a WHO/IDF Consultation. Geneva. Online: https://www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia
WHO: BMI. Online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
WINKLER, Gábor et al. (2011): Kockázatalapú diabétesz-szűrés háziorvosi praxisokban, felnőtt egyének körében. Diabetologia Hungarica, 19(2), 111–122. Online: https://diabet.hu/upload/diabetes/magazine/dh1102_01.pdf?web_id=